Sandoz (SIX: SDZ / OTCQX: SDZNY), the global leader in affordable medicines, will host its 2026 capital markets day on Tuesday, 8 September, at the London Stock Exchange, with a live webcast from 13:30 to 17:00 UK time. The event aims to provide investors and analysts with insights into how Sandoz intends to maximize value during what it calls the 'golden decade for biosimilars.' The formal part of the event will be webcast live, and details for accessing the webcast are available here. In-person attendance is by invitation only on a first-come, first-served basis.
In addition to the capital markets day, Sandoz plans to host an investor and analyst site visit in Slovenia from 9-10 November. This visit will provide further insight into the company's new biosimilars development and supply-chain hub. Attendance is also by invitation only and will not be webcast. These events come as Sandoz celebrates 20 years of pioneering biosimilars in 2026, underscoring its commitment to expanding access to biologic medicines.
The announcement is significant because Sandoz is positioning itself to capitalize on the growing biosimilars market, which is expected to experience substantial growth as patents on major biologic drugs expire. With net sales of USD 11.1 billion in 2025, Sandoz has a leading portfolio of approximately 1,300 medicines, addressing diseases from the common cold to cancer. The company's focus on biosimilars is part of its broader strategy to drive growth through affordable medicines, generating substantial healthcare savings globally.
The capital markets day will likely cover Sandoz's pipeline, manufacturing capabilities, and market expansion plans. The site visit in Slovenia will showcase the company's new hub, which is central to its biosimilars development and supply chain. This hub is expected to enhance Sandoz's ability to bring biosimilars to market efficiently, supporting its goal of reaching over one billion patients annually.
Investors and analysts will be keen to hear about Sandoz's financial outlook and how it plans to navigate competitive pressures and regulatory challenges. The events are part of Sandoz's ongoing efforts to communicate its strategy and value proposition to the investment community. As a standalone company since its spin-off from Novartis, Sandoz has been focusing on its core mission of providing affordable medicines, with biosimilars being a key growth driver.
The company's forward-looking statements caution that actual results may differ due to risks such as global economic conditions, exchange rates, legal provisions, and competitive activities. Nonetheless, Sandoz remains optimistic about its prospects in the biosimilars market, which it believes offers significant opportunities for value creation over the next decade.
